Peptide library
Tirzepatide
Approved product
Randomized evidence
Evidence record
- Product and route
- Subcutaneous injection.
- Approval scope
- Zepbound: weight management for eligible patients.
- Mechanism
- Activates GIP and GLP-1 receptors.
- Evidence
- Randomized trials.
- Limits
- Check other products separately.
- Safety context
- Severe or persistent gastrointestinal symptoms: contact a clinician.
A reading exercise
Imagine a page placing a tirzepatide research result beside an invitation to use a support service. Draw a line down a sheet of paper: put the measured result on one side and the service promise on the other. Now ask what was actually compared in the source. If the service itself was not part of that comparison, leave its promised effect in a separate box marked untested by this source. Apply the same exercise to psychotherapy or an AI tool. A nearby citation needs a clear connection to the claim; sharing a page does not supply that connection.
Questions to take away
- Was the offered service itself included in the comparison described by the source?
- Which sentence is about a measured result, and which describes the service?
- What separate evidence would be needed to evaluate the service promise?
Sources
Each date identifies a source check. It is separate from this page’s publication date.
- ZEPBOUND — NLM; checked
- Zepbound approval — FDA; checked